Study Type
Interventional - Drug
The objective of the AVERROES study was to determine if apixaban 5 mg BID (2.5 mg BID in selected patients) is superior to Acetylsalicylic Acid (81 to 324 mg QD) for preventing the composite outcome of stroke or systemic embolism in patients with atrial fibrillation, and at least one additional risk factor for stroke, who have failed or are unsuitable for vitamin K antagonist therapy.
Patients received active apixaban tablets and placebo ASA tablets, or placebo apixaban tablets and active ASA tablets.
Primary endpoint:
Composite of stroke or systemic embolism.
Interventional - Drug
Randomized double blind, double dummy parallel arm
36
433
5600
2007 - 2010
PHRI
Back To Top